Back to Journals » Clinical Interventions in Aging » Volume 2 » Issue 1

Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women

Authors Esteban Jódar-Gimeno

Published 15 April 2007 Volume 2007:2(1) Pages 163—174

Esteban Jódar-Gimeno

Endocrinology and Metabolism Service, University Hospital “12 de Octubre”, Madrid, Spain. Associate Professor of Medicine Universidad Complutense, Madrid, Spain

Objective: To review the pharmacological properties and the available clinical data of full length parathyroid hormone (PTH) in post-menopausal osteoporosis.

Sources: A MEDLINE search was completed, together with a review of information obtained from the manufacturer and from the medicine regulatory agencies.

Study and data selection: Studies were selected according to relevance and availability. Relevant information (design, objectives, patients’ characteristics, outcomes, adverse events, dosing, etc) was analyzed.

Results: Different studies have shown that, when administered intermittently as a subcutaneous injection in the abdomen, PTH increases bone mineral density (BMD) and prevents vertebral fractures. On completion of PTH therapy (up to 24 months), there is evidence that sequential treatment with alendronate is associated with a therapeutic benefit in terms of increase in BMD. Further trials are necessary to determine long-term safety and the role of PTH in combination with other treatments for osteoporosis and the effect of repeated cycles of PTH followed by an anti-catabolic agent. There are currently no completed comparative trials with other osteoporosis treatments.

Conclusions: Full length PTH, given intermittently as an abdominal subcutaneous injection, appears to be a safe and efficacious treatment option for high risk osteoporosis. More data are needed to determine its specific role in osteoporosis treatment.

Keywords: postmenopausal osteoporosis, anabolic therapy, PTH (1–84)

Download Article [PDF] 

Readers of this article also read:

The genetics of Alzheimer's disease

Bagyinszky E, Youn YC, An SSA, Kim SY

Clinical Interventions in Aging 2014, 9:535-551

Published Date: 1 April 2014

Postural stability and quality of life after guided and self-training among older adults residing in an institutional setting

Tuunainen E, Rasku J, Jäntti P, Moisio-Vilenius P, Mäkinen E, Toppila E, Pyykkö I

Clinical Interventions in Aging 2013, 8:1237-1246

Published Date: 16 September 2013

High-level activities of daily living and disease-specific mortality during a 12-year follow-up of an octogenarian population

Takata Y, Ansai T, Soh I, Awano S, Nakamichi I, Akifusa S, Goto K, Yoshida A, Fujii H, Fujisawa R, Sonoki K

Clinical Interventions in Aging 2013, 8:721-728

Published Date: 17 June 2013

Alteration patterns of trabecular bone microarchitectural characteristics induced by osteoarthritis over time

Lee JH, Chun KJ, Kim HS, Kim SH, Han P, Jun Y, Lim D

Clinical Interventions in Aging 2012, 7:303-312

Published Date: 10 August 2012

Endothelial function in a cardiovascular risk population with borderline ankle–brachial index

Kari Syvänen, Päivi Korhonen, Auli Partanen, et al

Vascular Health and Risk Management 2011, 7:97-101

Published Date: 23 February 2011

Walker use, but not falls, is associated with lower physical functioning and health of residents in an assisted-living environment

Daniel A Andersen, Bernard A Roos, Damian C Stanziano, Natasha M Gonzalez, Joseph F Signorile

Clinical Interventions in Aging 2007, 2:123-137

Published Date: 15 April 2007

Rivastigmine in the treatment of Alzheimer's disease: an update

Maria Luisa Onor, Marianna Trevisiol, Eugenio Aguglia

Clinical Interventions in Aging 2007, 2:17-32

Published Date: 15 April 2007

Immunological outcomes of exercise in older adults

David S Senchina, Marian L Kohut

Clinical Interventions in Aging 2007, 2:3-16

Published Date: 15 April 2007